Rickettsia parkeri Rickettsiosis and Its Clinical Distinction from Rocky Mountain Spotted Fever

Christopher D. Paddock, Richard W. Finley, Cynthia S. Wright, Howard N. Robinson, Barbara J. Schrodt, Carole C. Lane, Okechukwu Ekenna, Mitchell A. Blass, Cynthia L. Tamminga, Christopher A. Ohl, and Marina E. Eremeeva

Infectious Diseases Pathology Branch, Rickettsial Zoonoses Branch, and Office of the Director, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, and St. Joseph’s Hospital, Atlanta, Georgia; University of Mississippi Medical Center and Mississippi Department of Health, Jackson, and Singing River Hospital, Pascagoula, Mississippi; Wright’s Family Healthcare, Conway, South Carolina; Bernstein and Robinson Dermatology, Bel Air, Maryland; Dermatology Associates, Louisville, Kentucky; Lane Medical Group, Monroeville, Alabama; Naval Medical Center Portsmouth; Portsmouth, Virginia; Wake Forest University School of Medicine, Winston-Salem, North Carolina; and Tulane University School of Medicine, New Orleans, Louisiana

Background. Rickettsia parkeri rickettsiosis, a recently identified spotted fever transmitted by the Gulf Coast tick (Amblyomma maculatum), was first described in 2004. We summarize the clinical and epidemiological features of 12 patients in the United States with confirmed or probable disease attributable to R. parkeri and comment on distinctions between R. parkeri rickettsiosis and other United States rickettsioses.

Methods. Clinical specimens from patients in the United States who reside within the range of A. maculatum for whom an eschar or vesicular rash was described were evaluated by ≥1 laboratory assays at the Centers for Disease Control and Prevention (Atlanta, GA) to identify probable or confirmed infection with R. parkeri.

Results. During 1998–2007, clinical samples from 12 patients with illnesses epidemiologically and clinically compatible with R. parkeri rickettsiosis were submitted for diagnostic evaluation. Using indirect immunofluorescence antibody assays, immunohistochemistry, polymerase chain reaction assays, and cell culture isolation, we identified 6 confirmed and 6 probable cases of infection with R. parkeri. The aggregate clinical characteristics of these patients revealed a disease similar to but less severe than classically described Rocky Mountain spotted fever.

Conclusions. Closer attention to the distinct clinical features of the various spotted fever syndromes that exist in the United States and other countries of the Western hemisphere, coupled with more frequent use of specific confirmatory assays, may unveil several unique diseases that have been identified collectively as Rocky Mountain spotted fever during the past century. Accurate assessments of these distinct infections will ultimately provide a more valid description of the currently recognized distribution, incidence, and case-fatality rate of Rocky Mountain spotted fever.

An unnamed, apparently new rickettsia has been repeatedly isolated at the Rocky Mountain Laboratory during the past nine years from specimens of Amblyomma maculatum, a tick of wide distribution in the Southern States...the presumptive evidence from animal experimentation suggests that human infection might be confusingly similar to spotted fever.

—Ralph R. Parker, 1948 [1, p. 146]

In 1937, Parker et al. [2] identified a unique spotted fever rickettsia borne by the Gulf Coast tick (A. maculatum) (figure 1A); this rickettsia was eventually named Rickettsia parkeri in Parker’s honor. When these investigators infected guinea pigs with R. parkeri, they observed a febrile illness in the animals that was similar...
disease and RMSF, and discuss the epidemiological importance of these distinctions.

**PATIENTS AND METHODS**

**Patients.** Serum, whole blood, and skin biopsy specimens are routinely submitted to the Centers for Disease Control and Prevention (CDC) by clinicians and state health departments for specialized diagnostic tests when a spotted fever rickettsiosis is suspected in patients with compatible clinical signs and epidemiologic features. For patients residing within the US range of *A. maculatum* endemicity for whom an eschar or vesicular rash was reported to the CDC during 1998–2007, specimens were evaluated by ≥1 laboratory methods. Accompanying epidemiological and clinical data, of varying completeness, were provided by the submitting physician or public health worker. A confirmed case of *R. parkeri* rickettsiosis was defined by isolation of *R. parkeri* in cell culture or PCR amplification of *R. parkeri* DNA from a clinical specimen. A probable case was defined as a clinically and epidemiologically compatible illness, with ≥1 supportive serological or immunohistochemical test result, through use of group-specific assays for spotted fever group rickettsiae (SFGR).

**Indirect immunofluorescence assays.** Antigens of 4 species of SFGR (*R. parkeri* Hmac, *Rickettsia rickettsii* Sheila Smith, *Rickettsia akari* Hartford, and *Rickettsia amblyommii* GAT16) were selected on the basis of known or suggested associations with human disease in the United States. Rickettsiae were cultivated in Vero E6 cells and were purified using centrifugation through 25%–45% Renografin (Nycomed) gradients. The nuclear fraction was suspended in K-36 buffer, was irradiated, was spotted on glass slides, and was fixed in acetone. Fluorescein isothiocyanate–labeled, goat anti-human IgG (heavy chain– and light chain–specific) or anti-human IgM antibodies (Kirkegaard & Perry) were used at dilutions of 1:200 and 1:100, respectively. IgG was absorbed from serum samples before evaluation for IgM with use of a Mini Rapi-Sep-M kit (Panbio Diagnostics). Samples were screened at consecutive 2-fold serum dilutions, starting at 1:32, and titers were represented as the reciprocal of the last dilution exhibiting reactivity with the specific antigen. IgG and IgM titers ≥64 were considered to be positive for data analysis.

**Histology and immunohistochemistry.** Three-micrometer sections were cut from formalin-fixed, paraffin-embedded biopsy specimens of skin and were stained with hematoxylin-eosin and with use of an immunoperoxidase phosphatase technique with a polyclonal anti–*R. rickettsii* antiserum diluted at 1:500. In formalin-fixed tissues, this antiserum reacts with antigens of all known pathogenic SFGR that are indigenous to the United States, including *R. rickettsii*, *R. parkeri*, and *R. akari* [6, 10, 11].

**Cell culture.** Vero E6 cells were inoculated with triturated
skin biopsy specimens and were incubated at 34.5°C in a 5% CO₂-enriched atmosphere [6, 10]. Cultures were screened for infection with rickettsiae with use of acridine orange stain, and results were confirmed using molecular assays.

**Molecular analyses.** DNA was extracted, using a QIAamp DNA Mini Kit (Qiagen), from fresh biopsy samples of skin tissue; formalin-fixed, paraffin-embedded tissue sections; cell culture suspensions; and an *A. maculatum* specimen removed from a patient [4, 10]. Segments of the rickettsial 17-kilodalton antigen gene or the rickettsial outer membrane protein A gene (*ompA*) were amplified from these extracts with use of nested or seminested PCR assays [4, 12]. Purified amplicons were sequenced using an ABI PRISM 3.0 BigDye Terminator Cycle Sequencing kit (Applied Biosystems) or using a GenomeLab Sequencing kit (Applied Biosystems) and a 3100 Nucleic Acid Analyzer (Applied Biosystems). Sequences were compared with the 17-kD antigen gene or the rickettsial outer membrane protein A gene (*ompA*) of *R. rickettsii* as well as with rickettsial outer membrane protein A genes of *R. amblyommii* and *R. parkeri* by using the BLAST 2.0 program.

**Case report form evaluations.** RMSF case report forms (CRFs) submitted to the CDC were evaluated for the laboratory methods used to determine confirmed cases of RMSF for the period 1981–2005, as defined by the Council of State and Territorial Epidemiologists’ case definition for this disease [13]. These laboratory criteria included: (1) a ≥4-fold change in antibody titer reactive with *R. rickettsii*, (2) isolation of *R. rickettsii* in cell culture, (3) PCR amplification of DNA of *R. rickettsii*, or (4) immunostaining of *R. rickettsii* in a clinical specimen.

**Data analysis.** The qualitative reactivity (i.e., a positive or negative titer result) of each patient’s serum sample with *R. parkeri* antigen was compared with his or her serum reactivity to *R. rickettsii*, *R. akari*, or *R. amblyommii* antigens by using McNemar’s test and the κ coefficient (SAS, documentation 9.13, 2004; SAS Institute). For patients with ≥1 serum specimen, the first sample that showed a titer ≥64 to any SFGR antigen was used for these comparisons. A *P* value <.05 was considered to be statistically significant.

**RESULTS**

**Patient characteristics.** Six confirmed and 6 probable cases of *R. parkeri* rickettsiosis were identified in patients from Alabama, Florida, Kentucky, Maryland, Mississippi, South Carolina, and Virginia during 1998–2007 (figure 1 and table 1). Patients (8 men and 4 women) had an age range of 23–83 years (median age, 53 years). Ten patients (83%) became ill between late July and early September. Seven patients reported a tick bite, and eschars were identified definitively at bite sites for 6 patients. For 2 patients, ticks bites were identified definitively as caused by *A. maculatum*. The first recognized symptoms occurred 2–10 days (median duration, 5 days) after the tick bite and included a “sore” or “pimple” at the tick bite site (6 patients), fever (3), fatigue with myalgia or headache (2), and generalized rash (1). RMSF or rickettsialpox were included in the working diagnoses for 9 patients (75%).

All patients described low to moderate fever (median temperature, 39.2°C; range, 37.7°C–40.3°C) that persisted for 2–10 days (median duration, 5 days) after the tick bite and included a “sore” or “pimple” at the tick bite site (6 patients), fever (3), fatigue with myalgia or headache (2), and generalized rash (1). RMSF or rickettsialpox were included in the working diagnoses for 9 patients (75%).

All patients described low to moderate fever (median temperature, 39.2°C; range, 37.7°C–40.3°C) that persisted for 2–11 days (median duration, 7 days), and only 2 (17%) reported temperatures ≥40°C (table 2). Eschars were identified in 11 patients, which appeared as crusted, nonpruritic, and nonen-
der or mildly tender ulcers, 0.5–2 cm in greatest dimension, surrounded by an indurated, erythematous halo and, occasionally, by a few scattered petechiae (figure 2A–2D). These lesions were identified on the lower leg, shoulder, upper arm, groin, flank, toe, neck, or hand; 2 patients had multiple eschars. The recognition of the eschar preceded onset of fever by 0–4 days. A maculopapular or vesiculopapular exanthem, involving primarily the trunk and extremities, was identified on 10 patients within 0.5–4 days after the onset of fever (figure 2E and 2F). These lesions were pink, nonpruritic macules and papules, 0.2–0.5 cm in greatest dimension, and some contained a small central vesicle or pustule. The estimated number of these lesions had a range between ∼15 and several hundred. The exanthem involved the palms or soles of 5 patients and the face of 2 patients. Almost all patients reported myalgia and headache, most often described as mild. Nine patients (75%) described arthralgia. Tender lymphadenopathy in proximity to the eschar was documented for 3 patients. Only 1 patient reported nausea and vomiting; none reported diarrhea. Photophobia and neck stiffness were described by 2 patients, but no severe neurological manifestations were identified on physical examination.

Modest elevations of aspartate aminotransferase (median level, 56 U/L; range, 38–92 U/L) and alanine aminotransferase (median level, 78 U/L; range, 41–195 U/L) were observed in 7 of 9 and 4 of 8 patients, respectively. Mild thrombocytopenia (median platelet count, 145 × 10^6 platelets/L; range, 122–149 × 10^6 platelets/L) and leukopenia (median WBC count, 3.4 × 10^5 cells/L; range, 3.2–4.4 × 10^5 cells/L) were identified in 4 and 5, respectively, of 10 patients. Two patients with confirmed infection and 2 with probable infection were hospitalized for a median of 4 days (range, 2–9 days). Eleven patients received doxycycline and defervesced within 12–48 h after receipt of this antibiotic; 8 patients received 1–3 other antibiotics (i.e., penicillins, cephalosporins, or sulfa-containing antimicrobials) before receipt of doxycycline, and 1 patient recovered without receipt of a tetracycline-class drug.

**Indirect immunofluorescence assays.** Serum specimens collected from patients with confirmed and probable infection demonstrated broad IgM and IgG reactivity with all antigens, although the highest geometric titers were obtained using *R. rickettsii* as the antigen (table 3). Antibody titers ≥64 to each of the antigens were identified in serum samples from 4 patients with confirmed infection, including 3 samples with cross-reacting IgM and 4 with cross-reacting IgG; all confirmed cases had IgG reactive with *R. parkeri* and *R. rickettsii*. Titers ≥64 to each of the antigens, including 3 with cross-reacting IgM

---

**Table 2. Comparison of selected clinical features of *Rickettsia parkeri* rickettsiosis with those of Rocky Mountain spotted fever (RMSF) and rickettsialpox, as reported in well-characterized case series.**

| Clinical characteristic               | *R. parkeri* rickettsiosis (n = 12) | RMSF (n = 208) | Rickettsialpox (n = 197) |
|--------------------------------------|-------------------------------------|----------------|-------------------------|
| Fever                                | 100 (100)                           | 100 (100)      | 99 (100)                |
| Inoculation eschar(s)                |                                     |                |                         |
| Any                                  | 92 (100)                            | ND             | 92 (70)                 |
| Multiple eschars                     | 17 (100)                            | ND             | 14 (18)                 |
| Rash                                 |                                     |                |                         |
| Any type                             | 83 (100)                            | 92 (100)       | 100 (100)               |
| Macules or papules                   | 83 (100)                            | 83 (37)        | 100 (100)               |
| Petechiae                            | 17 (100)                            | 47 (80)        | ND                      |
| Vesicles or pustules                 | 42 (100)                            | ND             | 100 (82)                |
| On palms or soles                    | 45 (92)                             | 82 (70)        | 2 (91)                  |
| Myalgia                              | 92 (100)                            | 59 (98)        | 39 (9)                  |
| Headache                             | 83 (100)                            | 72 (100)       | 92 (100)                |
| Lymphadenopathy                      | 25 (100)                            | 20 (29)        | 17 (9)                  |
| Nausea or vomiting                   | 8 (100)                             | 60 (94)        | 7 (82)                  |
| Diarrhea                             | 0 (92)                              | 20 (94)        | ND                      |
| Coma, delirium, or seizure           | 0 (100)                             | 27 (86)        | 0 (100)                 |
| Hospitalization                      | 33 (100)                            | 78 (100)       | 18 (100)                |
| Death                                | 0 (100)                             | 7 (100)        | 0 (100)                 |

**NOTE.** Data are percentages of patients with characteristic (% of patients for whom frequency of the characteristic was specifically assessed). ND, feature not documented in the series evaluated.

* From references 6–8 and data herein.
* From references 14–17.
* From references 18–20.
Figure 2. Cutaneous lesions from patients with confirmed *Rickettsia parkeri* rickettsiosis. Inoculation eschars, representing the site of primary infection following a bite from an *R. parkeri*-infected tick, are present on the lateral aspect of the palm of patient 5 (A) and on the lower extremities of patient 4 (B–D). These lesions are 0.5–1.5 cm wide, with a central area of ulcerated or scabbed skin surrounded by a halo of erythema (A and B) or petechiae (C). Panel D shows multiple eschars on patient 4. The rash of *R. parkeri* rickettsiosis, as seen on patients 4 (E) and 5 (F), is a maculopapular or papulovesicular eruption on the trunk and extremities, occasionally involving the palms and soles.

and 4 with cross-reacting IgG, were identified in ≥1 serum samples from the patients with probable infection; 5 patients with probable infection had IgG that was reactive with *R. parkeri* and *R. rickettsii*. Four patients with confirmed *R. parkeri* infection had higher IgG titers with heterologous *R. rickettsii* antigens in ≥1 serum sample; however, qualitative analysis of each patient’s IgG reactivities with *R. parkeri* showed no statistically significant differences, when compared with the reactivities with any of the other 3 antigens (table 3). *R. amblyommii* was the only antigen that generated a significantly different IgM result from reaction with *R. parkeri* (*P* = .046).

**Histology and immunohistochemistry.** SFRG were identified in all eschar and rash specimens obtained for biopsy that were evaluated with use of immunohistochemical stain (table 1). Eschar samples obtained for biopsy showed extensive necrosis of the epidermis and superficial dermis (figure 3A) and prominent vasculitis of small- to medium-sized dermal vessels. Partially occlusive fibrin thrombi associated with localized hemorrhage were evident in some inflamed vessels (figure 3B). The mural and perivascular infiltrates comprised predominantly lymphocytes, macrophages, and occasional neutrophils (figure 3C), and similar inflammatory infiltrates often involved sweat glands, small nerves, and subcutaneous fat. Evaluation of a papular rash lesion from 1 patient showed an intraepidermal pustule and a diffuse mixed inflammatory cell infiltrate of the superficial to middermis comprising neutrophils and mononuclear cells, associated with karyorrhectic and necrotic debris and edema (figure 3D). SFRG were found predominantly in the cytoplasm of mononuclear cells (figures 3E and 3F). In most eschars, rickettsiae were sparse; however, relatively abundant SFRG were identified by immunohistochemical stain in the single rash lesion that was available for testing.

**Cell culture and molecular analyses.** Three isolates of *R. parkeri* (Portsmouth, Horry-SC2006, and Ft. Story strains) were obtained in Vero E6 cells and were confirmed by PCR and sequencing of 208-base pair segment of the 17-kilodalton antigen gene and 532–base pair segments of *ompA*. Homologous segments of *ompA* were also amplified from biopsy specimens
of fresh skin from 4 patients, formalin-fixed skin samples from 2 patients, and from an A. maculatum removed from 1 patient (table 1). All samples had 100% sequence identity with the corresponding ompA segment of R. parkeri (GenBank accession number U17008).

CRF evaluations. A total of 5735 laboratory-confirmed cases of RMSF were submitted to the CDC through CRFs for the 25-year interval that we evaluated; these represented ~50% of the total number of RMSF CRFs submitted to the CDC for this period. Only 305 (5.3%) of the total “confirmed” RMSF CRFs were actually confirmed by laboratory assay (i.e., culture isolation or PCR) with sufficient specificity to identify the infecting agent as R. rickettsii.

DISCUSSION

During 1998–2007, we identified 6 confirmed and 6 probable cases of R. parkeri rickettsiosis by passive surveillance of specimen submission to the CDC for diagnostic assays. Cases occurred across a wide geographic region that approximated the US distribution of A. maculatum. The probable cases were identified by assays specific only to the level of SFGR; however, other supportive data strongly suggest that each of the patients with probable cases was infected with R. parkeri. All had a relatively mild, eschar-associated rickettsiosis that occurred within the expected range of A. maculatum (e.g., coastal Mississippi, Alabama, and Florida), 2 sustained well-documented bites by A. maculatum (including 1 from which DNA of R. parkeri was subsequently detected by PCR), and 1 had a cutaneous lesion that was histopathologically and immunohistochemically identical to those observed with the confirmed cases.

When the clinical features that we identified for R. parkeri rickettsiosis were compared with those obtained from well-supported and classic descriptions of other historically recognized US spotted fevers (i.e., RMSF and rickettsialpox), many common characteristics were identified (table 2). R. parkeri rickettsiosis and RMSF are each characterized by fever, myalgia, malaise, headache, and a maculopapular eruption that may involve the palms or soles, and both diseases occur ~1 week after a tick bite [21]. Indeed, 50% of the patients described in this report received a diagnosis of RMSF at some point in their illnesses; however, R. parkeri rickettsiosis appears to be a milder illness than classically described RMSF. Notably, only 33% of the patients in this series were hospitalized, only 2 had a peak

---

### Table 3. Qualitative assessment of IgM and IgG antibody reactivity and geometric mean titers of confirmed and probable cases of Rickettsia parkeri rickettsiosis.

| Case and antibody | R. parkeri | Rickettsia rickettsii | Rickettsia akari | Rickettsia amblyommii |
|------------------|------------|----------------------|----------------|---------------------|
| **Confirmed (n = 6)** |            |                      |                |                     |
| IgM | No. of positive reactivities | 4 | 4 | 3 | 3 |
| Geometric mean titer (range) | 111 (32–256) | 74 (32–128) | 84 (32–256) | 64 (64–64) |
| IgG | No. of positive reactivities | 5 | 6 | 4 | 3 |
| Geometric mean titer (range) | 144 (32–1024) | 288 (64–1024) | 128 (32–1024) | 111 (32–512) |
| **Probable (n = 6)** |            |                      |                |                     |
| IgM | No. of positive reactivities | 5 | 4 | 4 | 2 |
| Geometric mean titer (range) | 111 (64–512) | 97 (32–1024) | 97 (32–512) | 108 (32–1024) |
| IgG | No. of positive reactivities | 5 | 5 | 4 | 5 |
| Geometric mean titer (range) | 256 (128–512) | 388 (64–1024) | 128 (64–512) | 256 (128–1024) |
| **Confirmed and probable (n = 12)** |            |                      |                |                     |
| IgM | No. of positive reactivities | 9 | 8 | 7 | 5a |
| Geometric mean titer (range) | 111 (32–512) | 84 (32–1024) | 90 (32–512) | 84 (32–1024) |
| IgG | No. of positive reactivities | 10 | 11 | 8 | 8 |
| Geometric mean titer (range) | 181 (32–1024) | 338 (64–1024) | 128 (32–1024) | 169 (32–1024) |

**NOTE.** Positive reactivities were determined by indirect immunofluorescence antibody assays, with use of antigens of various spotted fever group rickettsiae that are indigenous to the United States. Positive IgM and IgG reactivities with R. parkeri antigen, defined as serum titers /H11091 64, were compared with each of the other spotted fever rickettsial antigens by use of McNemar’s test (k coefficients, 0.38–0.64). For those patients with >1 serum specimen, geometric mean titers were calculated from the first specimen that showed a titer >64 to any antigen.

a P < .05 (k = 0.38).
temperature $>40^\circ C$, none had a temperature $\geq 40.5^\circ C$, none reported severe neurological disease or organ system failure, and there were no deaths. By comparison, 75% of patients with classic RMSF are hospitalized; 75% have peak temperatures $>40^\circ C$ (almost one-half have peak temperatures $\geq 40.5^\circ C$) [22]; $\sim 25\%$ develop stupor, delirium, ataxia, or coma; and the aggregate case-fatality rate derived from several contemporary and well-characterized US case series is $\sim 7\%$ (table 2) [14–17].

The natural history of well-characterized cases of untreated RMSF follows a progression of disease severity that most often culminates in hospitalization or death [1, 11, 14–17, 21–25]. By comparison, untreated patients with \textit{R. parkeri} rickettsiosis remained only moderately ill after as many as 7–10 days of fever. Other features that distinguish \textit{R. parkeri} rickettsiosis from RMSF include the occurrence of an eschar (identified in $>90\%$ of the patients in this series), a vesicular or pustular rash (observed in $\sim 40\%$ of the patients in this series), and the relative absence of nausea, vomiting, and diarrhea. By comparison, patients with classic RMSF rarely have eschars; there is seldom, if ever, documented vesicular or pustular exanthems; and gastrointestinal manifestations occur in $>60\%$ of patients [1, 14–17, 21–27].

\textit{R. parkeri} rickettsiosis also resembles rickettsialpox, an eschar-associated disease caused by \textit{R. akari}; and a diagnosis of rickettsialpox was considered for 25% of the patients in this series. However, most US cases of rickettsialpox have been described from large metropolitan centers in the northeastern states and are associated with the bite of the house mouse mite,
Liponyssoides sanguineus [28]. Indeed, a recently reported case of rickettsialpox from rural North Carolina occurred within the recognized range of A. maculatum and showed many clinical similarities with R. parkeri rickettsiosis [29]. The diagnostic dilemma posed by these clinically similar infections is compounded by the fact that antibodies generated to antigens of R. parkeri can react with R. rickettsii, R. akari, and other SFGR in conventional serological assays. The frequency with which R. parkeri rickettsiosis has been misidentified as RMSF or rickettsialpox is unknown, but the epidemiological consequences of misdiagnosis are potentially profound: if routine serological tests had been used to diagnose the 12 cases in this series, these patients could have been classified as 2 laboratory-confirmed and 9 laboratory-supported cases of RMSF by the current Council of State and Territorial Epidemiologists’ case definition for RMSF. From a clinical perspective, it is important to recognize that patients infected with R. parkeri, R. rickettsii, R. akari, or any other Rickettsia species will respond to therapy with doxycycline and that this therapy should never be delayed while awaiting diagnostic certainty [21].

Approximately 95% of the nearly 6000 “confirmed” US cases of RMSF reported to the CDC during 1981–2005 were identified by using serological assays that do not conclusively differentiate the various SFGR indigenous to the United States. The full impact of this level of nonspecific testing on the epidemiological accuracy of RMSF is unknown; however, antibodies to SFGR are detected in the general US population at relatively high frequencies—5%–10% in several studies [30, 31]—suggesting that confirmatory methods more rigorous than existing serological techniques should be considered when diagnosing cases of presumed spotted fever rickettsiosis. In several countries considerably smaller than the United States, including Algeria, France, Morocco, Portugal, and Spain, investigators have identified as many as 5 different and sympatrically distributed Rickettsia species which may cause clinically similar, yet epidemiologically distinct, rickettsial diseases. Many confirmed rickettsial pathogens (e.g., R. parkeri and Rickettsia massiliae) and rickettsiae of unknown pathogenicity in humans (e.g., Rickettsia rhipicephali, R. amblyommii, and serotypes 364D and Tillamook) reside in US ticks at frequencies far greater than those observed for R. rickettsii [4, 38–40]. It is possible that the true clinical spectrum, incidence, and distribution of RMSF in the United States have been clouded by blending epidemiological and clinical characteristics of several etiologically distinct diseases, caused by R. rickettsii, R. parkeri, and possibly other agents, under the umbrella diagnosis of RMSF. The descriptive mixing of these infections may extend throughout the Western hemisphere: R. parkeri has been detected recently in Argentina, Brazil, and Uruguay [41–43], and an eschar-associated disease that closely resembles R. parkeri rickettsiosis has also been described in several of these countries [44, 45]. In this context, rigorous efforts to obtain species-specific diagnoses through existing and developing technologies are needed to more accurately define the epidemiology and clinical presentation of spotted fever infections in the Americas.

Acknowledgments

We thank Gregory Dasch (CDC), for growing the rickettsiae and preparing the antigens used in the serological tests; James Hathanc (CDC), for the tick photography; and Sheryl Hand (Mississippi State Department of Health), Stephanie Thouvenel-Romans (Escambia County Department of Health), Jennifer Del Gallo, William Taylor, Robert Cox, and Mary Ziegler, for their assistance in collecting patient information and for their interest in this work.

Potential conflicts of interest. All authors: no conflicts.

References

1. Parker RR. Symptomatology and certain other aspects of Rocky Mountain spotted fever. In: Moulton FR, ed. Rickettsial diseases of man. Washington, DC: American Association for the Advancement of Science, 1948:139–46.
2. Parker RR, Kohls GM, Cox GW, Davis GE. Observations on an infectious agent from Amblyomma maculatum. Public Health Rep 1939; 54:1482–4.
3. Goddard J, Norment BR. Notes on the geographical distribution of the Gulf Coast tick, Amblyomma maculatum (Koch) [Acari: Ixodidae]. Entomol News 1983; 94:103–4.
4. Sumner JW, Durden LD, Goddard J, et al. Gulf Coast ticks (Amblyomma maculatum) and Rickettsia parkeri, United States. Emerg Infect Dis 2007; 13:751–3.
5. Parker RR. A pathogenic rickettsia from the Gulf Coast tick, Amblyomma maculatum. New York: Proc Third Int Cong Microbiol, 1940:390–1.
6. Paddock CD, Sumner JW, Comer JA, et al. Rickettsia parkeri: a newly recognized cause of spotted fever rickettsiosis in the United States. Clin Infect Dis 2004; 38:805–11.
7. Finley RW, Goddard J, Raoult D, Ereameva ME, Cox RD, Paddock CD. Rickettsia parkeri: a case of tick-borne, eschar-associated spotted fever in Mississippi [abstract 188]. In: Program and abstracts of the International Conference on Emerging Infectious Diseases 2006 (Atlanta, GA). Washington, DC: American Society for Microbiology, 2006:110.
8. Whitman TJ, Richards AL, Paddock CD, et al. Rickettsia parkeri infection after tick bite, Virginia. Emerg Infect Dis 2007; 13:334–6.
9. Raoult D, Paddock CD. Rickettsia parkeri and other spotted fevers in the United States. N Engl J Med 2005; 353:626–7.
10. Paddock CD, Koss T, Ereameva ME, Dasch GE, Zaki SR, Sumner JW. Isolation of Rickettsia akari from eschars of patients with rickettsialpox. Am J Trop Med Hyg 2006; 75:732–8.
11. Paddock CD, Greer PW, Ferebee TL, et al. Hidden mortality attributable to Rocky Mountain spotted fever: immunohistochemical detection of fatal, serologically unconfirmed disease. J Infect Dis 1999; 179:1469–76.
12. Ereameva ME, Bosserman EA, Demma L, Zambrano ML, Blau DM, Dasch GA. Isolation and identification of Rickettsia massiliae from Rhipicephalus sanguineus ticks collected in Arizona. Appl Environ Microbiol 2006; 72:5569–77.
13. Swerdlow D, Nicholson W, Anderson A, et al. Revision of the surveillance case definition for Rocky Mountain spotted fever. Available at: http://www.cste.org/PS/2007ps/pdf/110-11-110-07-ID-05.pdf. Accessed 18 September 2008.
14. Hazard GW, Ganz RN, Nevin RW, et al. Rocky Mountain spotted fever 2005.
in the eastern United States: thirteen cases from the Cape Cod area of Massachusetts. N Engl J Med 1969; 280:57–62.
15. Kaplowitz LG, Fischer J, Sparling PF. Rocky Mountain spotted fever: a clinical dilemma. Curr Clin Top Infect Dis 1981; 2:89–108.
16. Kirk JL, Fine DP, Sexton DJ, Muchmore HG. Rocky Mountain spotted fever: a clinical review based on 48 confirmed cases. Medicine 1990; 69:35–45.
17. Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected vector in Arizona. N Engl J Med 2005; 353:587–94.
18. Greenberg M, Pellitteri O, Klein IF, Huebner RJ. Rickettsialpox—a newly recognized rickettsial disease. II. Clinical observations. J Am Med Assoc 1947; 133:901–6.
19. Rose HM. The clinical manifestations and laboratory diagnosis of rickettsialpox. Ann Intern Med 1949; 31:871–83.
20. Koss T, Carter EL, Grossman ME, et al. Increased detection of rickettsialpox in a New York City hospital following the anthrax outbreak of 2001. Arch Dermatol 2003; 139:1545–52.
21. Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis—United States. MMWR 2006; 55(RR-4):1–27.
22. Harrell GT. Rocky Mountain spotted fever. Medicine 1949; 28:333–70.
23. Wolbach SB. Studies on Rocky Mountain spotted fever. J Med Res 1934; 70:393–408.
24. Zavala-Castro JE, Zavala-Velázquez, Walker DH, et al. Fatal human infection with Rickettsia rickettsii, Yucatán, Mexico. Emerg Infect Dis 2006; 12:672–5.
25. Paddock CD, Fernandez S, Echenique GA, et al. Rocky Mountain spotted fever in Argentina. Am J Trop Med Hyg 2008; 78:887–92.
26. Ramphal R, Kluge R, Cohen V, Feldman R. Rocky Mountain spotted fever and jaundice: two consecutive cases acquired in Florida and a review of the literature on this complication. Arch Intern Med 1978; 138:260–3.
27. Walker DH, Gay RM, Valdes-Dapena M. The occurrence of eschars in Rocky Mountain spotted fever. J Am Acad Dermatol 1981; 4:571–6.
28. Paddock CD, Zaki SR, Koss T, et al. Rickettsialpox in New York City: a persistent urban zoonosis. Ann NY Acad Sci 2003; 990:36–44.
29. Kruessell A, Comer JA, Sexton DJ. Rickettsialpox in North Carolina. Emerg Infect Dis 2002; 8:727–8.
30. Graf PCF, Chretien JP, Ung L, Gaydos JC, Richards AL. Prevalence of seropositivity to spotted fever group rickettsiae and Anaplasma phagocytophilum in a large, demographically diverse US sample. Clin Infect Dis 2008; 46:70–7.
31. Marshall GS, Stout GG, Jacobs RF, et al. Antibodies reactive to Rickettsia rickettsii among children living in the southeast and south central regions of the United States. Arch Pediatr Adolesc Med 2003; 157:443–8.
32. Parola P, Paddock CD, Raoult D. Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. Clin Microbiol Rev 2003; 16:719–36.
33. de Sousa R, Barata D, Vitorino L, Santos-Silva M, et al. Rickettsia sibirica isolation from a patient and detection in ticks, Portugal. Emerg Infect Dis 2006; 12:1103–8.
34. Bitam J, Parola P, Matsumoto K, et al. First molecular detection of R. conorii, R. aeschlimanni, and R. massiliae in ticks in Algeria. Ann NY Acad Sci 2006; 1078:368–72.
35. Sarih M, Socolovschi C, Boudebourch N, Hassar M, Raoult D, Parola P. Spotted fever group rickettsiae in ticks, Morocco. Emerg Infect Dis 2008; 14:1067–73.
36. Fernández-Soto P, Pérez-Sánchez R, Álamo-Sanz R, Encinas-Grande A. Spotted fever group rickettsiae in ticks feeding on humans in northwestern Spain: is Rickettsia conorii vanishing? Ann NY Acad Sci 2006; 1078:331–3.
37. Márquez FJ, Rodríguez-Liébana J, Sorijuer RC, et al. Spotted fever group Rickettsia in brown dog ticks Rhipicephalus sanguineus in southwestern Spain. Parasitol Res 2008; 103:119–22.
38. Paddock CD. Rickettsia parkeri as a paradigm for multiple causes of tick-borne rickettsioses in the Western hemisphere. Ann N Y Acad Sci 2005; 1063:315–26.
39. Wísko M, Hu R, Dasch GA, et al. Detection and identification of spotted fever group rickettsiae in Dermacentor species from southern California. J Med Entomol 2008; 45:509–16.
40. Apperson CS, Engber B, Nicholson WL, et al. Tick-borne diseases in North Carolina: is “Rickettsia amblyommii” a possible cause of rickettsiosis reported as Rocky Mountain spotted fever? Vector Borne Zoonotic Dis 2008; 8:1–10.
41. Venzal JM, Portillo A, Estrada-Peña A, Castro O, Cabrera PA, Oteo JA. Rickettsia parkeri in Amblyomma triste from Uruguay. Emerg Infect Dis 2004; 10:1493–5.
42. Silva V, Pacheco RC, Szabó MPJ, Ramos HG, Labruna MB. Rickettsia parkeri in Brazil. Emerg Infect Dis 2007; 13:1111–3.
43. Nava S, Elshewany Y, Eremeeva ME, Sumner JW, Mastropaolo M, Paddock CD. Rickettsia parkeri in Argentina. Emerg Infect Dis (in press).
44. Conti Díaz IA. Rickettsiosis por Rickettsia conorii (fiebre botonosa del Mediterráneo; fiebre de Marsella): estado actual en Uruguay. Rev Med Uruguay 2001; 17:119–24.
45. Seijo A, Picollo M, Nicholson WL, Paddock CD. Fiebre manchada por rickettsias en el Delta del Parana: una enfermedad emergente. Medicina (Buenos Aires). 2007;67:723–6.

Note added in proof. During July–September 2008, 4 additional cases of R. parkeri rickettsiosis, supported by results of serological or immunohistochemical assays, were identified in the course of diagnostic evaluations at the CDC. These patients, from Florida, Mississippi, North Carolina, and South Carolina, each had a relatively mild, eschar-associated, febrile illness with a maculopapular or papulovesicular rash that responded promptly to therapy with doxycycline.